You are here
Development of a Caregiver Application and AI-Enabled Intelligent Assistant to Support Families and Formal Care Providers in Caring for Persons with Alzheimer's Disease and Related Dementias
Phone: (608) 890-2578
Email: nwerner3@wisc.edu
Phone: (619) 804-1855
Email: dcelliott50@gmail.com
Address:
Type: Nonprofit College or University
PROJECT ABSTRACT
Family caregivers face daunting challenges in caring for persons with Alzheimer’s disease. Currently, there is
no widely available mechanism to provide real-time, context sensitive support to informal AD caregivers that can
address the specific care needs of each AD patient. To address this critical gap, we developed CareVirtue, an
innovative web/mobile application for family caregivers that also assists formal care providers helping these
families. During this Phase I project we will validate the CareVirtue web/mobile application as a method for
caregivers to document daily care interactions with AD patients, and establish the utility of the generated data to
develop predictive models for an intelligent caregiver assistant application.
Looking ahead, our long term goal is to commercialize an AI-enabled intelligent caregiver assistant application
that provides on demand, highly-relevant information about AD patients to care teams, which will ameliorate
caregiver stress andamp; burden, reduce health care expenditures, and improve quality of care for both AD patients
and their caregivers.PROJECT NARRATIVE
Family caregivers face daunting challenges in caring for persons with Alzheimer’s disease. Currently, there is
no widely available mechanism to provide real-time, context sensitive support to informal AD caregivers that can
address the specific care needs of each AD patient. During this project we will perform usability and feasibility
testing for the CareVirtue web/mobile application, and also develop initial predictive models for an AI-enabled
intelligent caregiver assistant application. This intelligent caregiver assistant application will be validated in a
larger Phase 2 trial.
* Information listed above is at the time of submission. *